Acromegaly

Acromegaly is the clinical syndrome of chronic GH and IGF-1 excess in an adult with fused epiphyses. More than 95% of cases are caused by a benign GH-secreting pituitary somatotroph adenoma; GH pulses stimulate hepatic and peripheral IGF-1 production, and it is IGF-1 — not GH itself — that drives most of the syndrome's tissue growth and metabolic effects and that serves as the key biomarker for both diagnosis and ongoing monitoring, since a single random GH level is uninterpretable given GH's pulsatile, minute-to-minute secretion pattern.^[1] The same pathophysiology occurring before epiphyseal closure produces gigantism (linear overgrowth) rather than acromegaly — a pediatric distinction covered in Special Populations.

Onset is insidious: facial and acral (hand/foot) changes progress so gradually that patients, families, and even treating clinicians often do not notice them, and diagnosis is typically made 7-10 years after the biological onset of disease — frequently only after a systemic complication (new diabetes, sleep apnea, treatment-resistant hypertension, or an incidental pituitary mass on imaging for another reason) prompts the workup that finally connects the dots. Acromegaly is disease-modifying rather than curable for many patients: transsphenoidal surgery achieves biochemical remission in a majority of microadenomas but a minority of larger or invasive macroadenomas, so a substantial proportion of patients need lifelong medical therapy, and every patient — controlled or not — needs lifelong monitoring for the complications that drive most of the disease's excess morbidity and mortality.^[1] The single most useful thing a pharmacist can track at every visit is whether IGF-1 is normalized for the patient's age and sex, since biochemical control is what predicts reduced complication risk and improved life expectancy.

• A sporadic GH-secreting pituitary somatotroph adenoma — the cause in more than 95% of cases, with no identifiable predisposing lifestyle factor.
• Multiple endocrine neoplasia type 1 (MEN1) — pituitary adenoma alongside parathyroid and pancreatic neuroendocrine tumors.
• Familial isolated pituitary adenoma (FIPA), often linked to an AIP gene mutation, particularly when acromegaly presents at a young age or with a family history of pituitary adenoma.
• McCune-Albright syndrome or Carney complex — rare genetic syndromes that can include GH-secreting pituitary disease among their features.
• Extremely rare: ectopic growth-hormone-releasing hormone (GHRH) secretion from a neuroendocrine tumor causing pituitary somatotroph hyperplasia, or, rarer still, ectopic GH secretion from a non-pituitary tumor.^[1]

Also refer to endocrinology (and neurosurgery, if a pituitary mass is confirmed) for any newly suspected diagnosis — biochemical confirmation, pituitary imaging, and surgical planning should not be managed outside specialist care — as well as for persistent disease after surgery, or any patient being considered for medical therapy escalation or radiotherapy.

Screening test

Measure IGF-1 against an age- and sex-matched reference range — this is the preferred first test. A single random GH level is not useful for screening: GH is secreted in pulses throughout the day and a normal random value does not exclude acromegaly, while a modestly elevated one does not confirm it.^[1]

Confirmatory test

An elevated or equivocal IGF-1 in a patient with a compatible clinical picture is confirmed with a 75 g oral glucose tolerance test (OGTT), measuring GH at baseline and every 30 minutes for 2 hours. Failure of GH to suppress below the assay-specific cutoff (commonly under 1 ng/mL, or under 0.4 ng/mL with newer ultrasensitive assays) confirms the diagnosis. A normal suppression response effectively excludes acromegaly in a patient not already on somatostatin analog therapy (which itself can blunt the OGTT response and make the test unreliable).^[1]

After biochemical confirmation

• Pituitary MRI with contrast to localize and characterize the adenoma (size, cavernous sinus invasion, proximity to the optic chiasm) and guide surgical planning.
• Formal visual field testing for any tumor abutting or compressing the optic chiasm.
• A full pituitary hormone panel (prolactin, TSH/free T4, LH/FSH with testosterone or estradiol, morning cortisol or ACTH stimulation testing as indicated) — to identify prolactin co-secretion (common, since somatotroph and lactotroph cells share a lineage) and any coexisting hypopituitarism from mass effect.
• Baseline complication screening — echocardiogram, a sleep study if symptoms suggest sleep apnea, fasting glucose/HbA1c, and colonoscopy — since these findings shape both the urgency of treatment and the long-term monitoring plan (see Monitoring & Follow-Up).^[2]

• Normalize IGF-1 for the patient's age and sex — the primary biochemical control target.^[3]
• Achieve a GH nadir under 1 ng/mL on OGTT where the test remains interpretable (not a valid marker in a patient on pegvisomant — see Special Populations/Common Errors).
• Control or reverse mass effect — relieve visual field compromise, resolve headache, and preserve or restore normal pituitary function.
• Prevent, detect early, or manage the systemic complications: cardiomyopathy, hypertension, sleep apnea, diabetes, colon polyps, and arthropathy.
• Avoid iatrogenic hypopituitarism from treatment itself (surgery or radiotherapy), and replace any hormone deficiency promptly when it occurs.
• Restore quality of life and reduce the excess mortality risk associated with sustained, uncontrolled disease.

• Endoscopic transsphenoidal surgery — outcomes are strongly volume-dependent; referral to a high-volume pituitary surgical center meaningfully improves remission rates and lowers complication risk compared with an occasional pituitary operator.^[1]
• Stereotactic radiosurgery (preferred over conventional fractionated radiotherapy where the tumor geometry allows) for residual or recurrent disease not controlled by surgery plus optimized medical therapy. Its GH/IGF-1-lowering effect is delayed, often by several years, so medical therapy is continued during this interval, and lifelong monitoring for radiotherapy-induced hypopituitarism is required even after the tumor itself is controlled.^[1]
• Continuous positive airway pressure (CPAP) for confirmed obstructive sleep apnea — treat this in parallel with definitive GH/IGF-1-lowering therapy, not instead of it, since airway soft-tissue overgrowth may only partially reverse with biochemical control.
• Coordinated, multidisciplinary follow-up (endocrinology, neurosurgery, cardiology, sleep medicine, and dentistry/orthodontics as needed) — this is a lifelong-monitoring condition even in patients who achieve biochemical remission.
• Patient education on the rationale for lifelong complication screening, since many of the downstream risks (cardiac, colonic, metabolic) are asymptomatic until advanced.

Pediatrics

GH excess before epiphyseal fusion produces gigantism — linear overgrowth in height, in addition to the same soft-tissue and organ changes seen in adults — rather than isolated acromegaly. The underlying pathophysiology, diagnostic approach (IGF-1 screening, OGTT confirmation using pediatric reference ranges, pituitary MRI), and surgery-first treatment sequence are the same as in adults.

Older adults

Baseline cardiovascular and metabolic comorbidity burden is typically higher, making complete cardiac and sleep apnea workup before surgery more consequential, not less — do not skip baseline echocardiography or sleep screening in an older patient because comorbidities seem to already explain the symptoms.

Hepatic and renal considerations

Pegvisomant carries a real hepatotoxicity risk and needs more frequent liver enzyme monitoring, particularly during the first 6 months and after any dose increase; avoid it in a patient with significant active hepatic impairment. Somatostatin analogs do not require routine dose adjustment for renal impairment but should still be used with the same monitoring as in any patient.

Drug interactions

Somatostatin analogs (octreotide, lanreotide, pasireotide) suppress insulin and glucagon secretion and can cause either hyperglycemia or hypoglycemia — anticipate the need to adjust diabetes medications, more so with pasireotide. They also slow gallbladder motility and increase cholelithiasis risk (periodic ultrasound if symptomatic), and can cause bradycardia — use added caution with concurrent beta-blockers or other bradycardia-inducing drugs. Pegvisomant improves insulin sensitivity as GH excess resolves, often requiring a reduction in insulin or sulfonylurea dose to avoid hypoglycemia. Cabergoline should not be combined with other ergot-derived medications, and its efficacy is reduced by concurrent dopamine-antagonist drugs (e.g., some antipsychotics, metoclopramide).

• IGF-1 approximately every 12 weeks during medical therapy initiation or dose titration, then every 6-12 months once the patient is stable and biochemically controlled.^[3]
• Pituitary MRI — first around 12 weeks after surgery, then per residual-tumor risk; continue periodic MRI in any patient on pegvisomant even once IGF-1 is normalized, since pegvisomant has no direct anti-tumor effect and biochemistry alone will not detect tumor regrowth.
• Echocardiogram at baseline and as clinically indicated; more frequent monitoring is reasonable in a patient on higher-dose cabergoline given the valvulopathy risk at acromegaly-level dosing.
• Sleep apnea screening/re-screening based on symptoms, since airway soft-tissue changes may only partially reverse with biochemical control.
• Fasting glucose or HbA1c at baseline and periodically, with closer monitoring in a patient on pasireotide given its materially higher hyperglycemia risk.
• Colonoscopy at diagnosis (particularly age 40 and over) with repeat interval individualized to findings and ongoing biochemical control — more frequent surveillance for a patient with prior polyps or persistently uncontrolled disease.^[2]
• Annual visual field testing for any patient with a history of chiasmal involvement.
• Liver enzymes for a patient on pegvisomant — baseline, then periodically (more frequently in the first 6 months and after any dose increase).
• Periodic full pituitary function panel to detect treatment- or tumor-related hypopituitarism, with prompt hydrocortisone, levothyroxine, or sex hormone replacement as needed.
• Ongoing assessment of joint symptoms — acromegalic arthropathy can persist and progress even after the underlying GH/IGF-1 excess is controlled.

1. Confirm adherence and correct injection technique for depot somatostatin analog therapy — a missed or poorly administered dose is a common and easily fixed cause of apparent treatment failure.
2. Confirm the somatostatin analog dose has actually been optimized/titrated to its effective range before concluding the drug class has failed.
3. Re-image with pituitary MRI to exclude tumor regrowth or a previously unrecognized residual tumor as the driver of persistent biochemical disease.
4. For confirmed inadequate response despite an optimized 1st-generation SSA dose, switch to pasireotide LAR, or add or switch to pegvisomant — combination SSA plus pegvisomant is a reasonable and commonly used option.
5. Add cabergoline for mild residual IGF-1 elevation, or when prolactin co-secretion is present.
6. If IGF-1 remains elevated despite optimized combination medical therapy, or the tumor continues to grow, refer for repeat surgery (if a resectable target remains) or stereotactic radiosurgery.

• Relying on a single random GH level to screen for or rule out acromegaly — GH's pulsatile secretion makes this uninterpretable; use IGF-1 first.
• Using GH to monitor treatment response in a patient on pegvisomant — it blocks the GH receptor rather than lowering GH secretion, so GH levels are not a valid marker on this drug; use IGF-1.
• Assuming a normalized IGF-1 on pegvisomant means the tumor itself is controlled — it has no direct anti-tumor effect, so periodic MRI is still required.
• Not screening for complications (cardiac, sleep apnea, glucose, colon) at diagnosis and assuming they will simply resolve once GH/IGF-1 is controlled — some, particularly arthropathy, can persist regardless.
• Treating an isolated elevated IGF-1 or GH found incidentally without confirmatory OGTT and clinical correlation.
• Declaring somatostatin analog therapy a failure before the dose has actually been titrated to its effective range over an adequate trial period (about 3 months).
• Missing pituitary apoplexy or acute hypopituitarism as an emergency in a patient with a known pituitary adenoma who develops sudden headache, visual change, or hypotension.
• Overlooking cabergoline's valvulopathy risk at the higher doses used in acromegaly (compared with typical prolactinoma dosing) and skipping baseline/periodic echocardiography.
• Not considering combination medical therapy (SSA plus pegvisomant, or plus cabergoline) before escalating straight to radiotherapy.
• Interpreting IGF-1 and GH by adult reference ranges in a pregnant patient — both rise physiologically in pregnancy and are not reliable disease markers in that setting.

How to use this table: Doses are adult doses and require patient-specific confirmation. Select any linked drug name to open its complete Pharmasist Drug Database page.

Somatostatin analogs — first generation (1st-line medical therapy)

Both agents are equally reasonable first choices; selection often comes down to injection preference and local administration logistics.

Somatostatin analog — second generation / multireceptor (SSA-resistant disease)

Reserve for disease genuinely resistant to an optimized trial of a first-generation SSA, given its materially higher hyperglycemia risk.

Growth hormone receptor antagonist

Blocks the GH receptor rather than lowering GH secretion — GH levels are not a valid marker of response on this drug; use IGF-1 only.

Dopamine agonists

The least effective medical option used alone; most useful for mild residual IGF-1 elevation, prolactin co-secretion, or as an add-on to a somatostatin analog or pegvisomant.

Combination medical therapy

A reasonable escalation option before moving to radiotherapy — see Clinical Decision Algorithm, Algorithm C.